On Thursday, iBio, Inc. (NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a ...

(NYSE:IBIO) expanded its cardiometabolic and obesity treatment development program by in-licensing a potentially long-acting anti-myostatin antibody from AstralBio, Inc. In March, iBio ...

Scientists in Israel have created the first nano-robot antibodies designed to fight cancer. The first human trial for the new nano-robots will start soon, and it will determine just how effective ...

In March, iBio collaborated with AstralBio to discover, engineer, and develop antibodies to treat obesity and other cardiometabolic conditions. The antibody, now named IBIO-600, was identified by ...

Researchers leverage snake venom components to develop new hypertension treatments Innovative compounds in snake venom spark ...

INR:3044. pocket rummy 5 buffalo wild wings calories Primary school students cheated in cancer research awards? Yunnan ...